92 related articles for article (PubMed ID: 12014657)
1. Growth inhibition of mouse autochthonous skin cancer by oral administration of new serine protease inhibitor ONO-3403.
Ohkoshi M; Okuda S
Anticancer Res; 2002; 22(2A):821-3. PubMed ID: 12014657
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of mouse skin tumor by serine protease inhibitor ONO-3403.
Ohkoshi M; Okuda S
Anticancer Res; 2001; 21(3B):1803-8. PubMed ID: 11497262
[TBL] [Abstract][Full Text] [Related]
3. Effects of serine protease inhibitor FOY-305 and heparin on the growth of squamous cell carcinoma.
Ohkoshi M; Akagawa T; Nakajima M
Anticancer Res; 1993; 13(4):963-6. PubMed ID: 8352567
[TBL] [Abstract][Full Text] [Related]
4. Decrease in growth factor receptors after treatment with serine protease inhibitor ONO-3403.
Hiwasa T; Shimada H; Ochiai T; Liu TL; Yuasa Y; Takiguchi M; Ohkoshi M
Int J Oncol; 2002 Apr; 20(4):797-802. PubMed ID: 11894127
[TBL] [Abstract][Full Text] [Related]
5. Potent growth-suppressive activity of a serine protease inhibitor, ONO-3403, toward malignant human neuroblastoma cell lines.
Hiwasa T; Kondo K; Nakagawara A; Ohkoshi M
Cancer Lett; 1998 Apr; 126(2):221-5. PubMed ID: 9585070
[TBL] [Abstract][Full Text] [Related]
6. Modelling of tumour--host coexistence In vitro in the presence of serine protease inhibitors.
Engi H; Gyémánt N; Ohkoshi M; Amaral L; Molnár J
In Vivo; 2009; 23(5):711-5. PubMed ID: 19779105
[TBL] [Abstract][Full Text] [Related]
7. Effect of oral administration of protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on the growth of 3-methylcholanthrene-induced carcinoma in mice.
Ohkoshi M; Fujii S
Gan; 1982 Feb; 73(1):108-10. PubMed ID: 7117738
[TBL] [Abstract][Full Text] [Related]
8. Growth-suppressive activities of serine protease inhibitors, ONO-3403 and ONO-5046, toward normal and transformed murine fibroblasts.
Hiwasa T; Ohkoshi M
Anticancer Res; 1996; 16(4A):1823-6. PubMed ID: 8712707
[TBL] [Abstract][Full Text] [Related]
9. Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor.
Ikeda T; Murakami K; Hayakawa Y; Fujii H; Ohkoshi M; Saiki I
Anticancer Res; 1998; 18(6A):4259-65. PubMed ID: 9891476
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer.
Kobayashi H; Yagyu T; Inagaki K; Kondo T; Suzuki M; Kanayama N; Terao T
Cancer; 2004 Feb; 100(4):869-77. PubMed ID: 14770446
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of growth of 3-methylcholanthrene-induced mouse skin tumor by protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate.
Ohkoshi M
Gan; 1981 Dec; 72(6):959-64. PubMed ID: 7341342
[TBL] [Abstract][Full Text] [Related]
12. [Protease inhibitors as anticancer chemotherapy--experimental and clinical studies].
Ohkoshi M
Gan To Kagaku Ryoho; 1995 Mar; 22(4):417-30. PubMed ID: 7887633
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil elastase inhibitor (ONO-5046-Na) inhibits the growth of human lung cancer cell lines transplanted into severe combined immunodeficiency (scid) mice.
Inada M; Yamashita J; Ogawa M
Res Commun Mol Pathol Pharmacol; 1997 Aug; 97(2):229-32. PubMed ID: 9344234
[TBL] [Abstract][Full Text] [Related]
14. Complete inhibition of spontaneous pulmonary metastasis of human lung carcinoma cell line EBC-1 by a neutrophil elastase inhibitor (ONO-5046.Na).
Inada M; Yamashita J; Nakano S; Ogawa M
Anticancer Res; 1998; 18(2A):885-90. PubMed ID: 9615736
[TBL] [Abstract][Full Text] [Related]
15. Effect of the synthetic protease inhibitor [N,N-dimethylcarbamoyl-methyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on carcinogenesis by 3-methylcholanthrene in mouse skin.
Ohkoshi M; Fujii S
J Natl Cancer Inst; 1983 Nov; 71(5):1053-7. PubMed ID: 6580482
[TBL] [Abstract][Full Text] [Related]
16. Chronic oral administration of protease inhibitor decreases CCK-A receptor mRNA expression but increases pancreatic growth in rats.
Fukumitsu K; Nakamura H; Otsuki M
Pancreas; 2001 Mar; 22(2):179-85. PubMed ID: 11249073
[TBL] [Abstract][Full Text] [Related]
17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
18. Effects of epidermal chalone and epidermal growth factor on a transplantable epidermal carcinoma (Hewitt) of the mouse in vivo.
Bertsch S; Marks F
Cancer Res; 1979 Jan; 39(1):239-43. PubMed ID: 153788
[No Abstract] [Full Text] [Related]
19. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
20. CCK-, secretin-, and cholinergic-independent pancreatic fluid hypersecretion in protease inhibitor-treated rats.
Yamamoto M; Shirohara H; Otsuki M
Am J Physiol; 1998 Feb; 274(2):G406-12. PubMed ID: 9486196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
